Phibro (PAHC) Reports Q3 Earnings: What Key Metrics Have to Say

Phibro Animal Health (PAHC) reported $263.2 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 7.1%. EPS of $0.31 for the same period compares to $0.29 a year ago.

The reported revenue represents a surprise of +4.52% over the Zacks Consensus Estimate of $251.82 million. With the consensus EPS estimate being $0.29, the EPS surprise was +6.90%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Phibro performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Net Sales by Region- Latin America and Canada: $53.65 million versus $52.85 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -0.4% change.
  • Net Sales by Region- Europe, Middle East and Africa: $33.18 million versus $30.57 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +17.8% change.
  • Net Sales by Region- United States: $159.31 million compared to the $151.03 million average estimate based on two analysts. The reported number represents a change of +7.3% year over year.
  • Net Sales by Region- Asia Pacific: $17.08 million versus the two-analyst average estimate of $17.37 million. The reported number represents a year-over-year change of +13.2%.
  • Net Sales- Animal Health: $181.33 million compared to the $171.38 million average estimate based on two analysts. The reported number represents a change of +10.3% year over year.
  • Net Sales- Mineral Nutrition: $64.23 million versus the two-analyst average estimate of $62.49 million. The reported number represents a year-over-year change of +2.1%.
  • Net Sales- Animal Health- Vaccines: $32.92 million compared to the $29.76 million average estimate based on two analysts. The reported number represents a change of +25.7% year over year.
  • Net Sales- Animal Health- MFAs and other: $108.22 million versus $94.06 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +16.1% change.
  • Net Sales- Animal Health- Nutritional Specialties: $40.19 million compared to the $47.56 million average estimate based on two analysts. The reported number represents a change of -10.7% year over year.
  • Net Sales- Performance Products: $17.66 million versus $17.97 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -3.5% change.
  • Adjusted EBITDA- Animal Health: $36.52 million versus the two-analyst average estimate of $35.85 million.
  • Adjusted EBITDA- Corporate: -$13.90 million versus -$14.29 million estimated by two analysts on average.
View all Key Company Metrics for Phibro here>>>

Shares of Phibro have returned +27.8% over the past month versus the Zacks S&P 500 composite's -0.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Top 5 Dividend Stocks for Your Retirement

Zacks targets 5 well-established companies with solid fundamentals and a history of raising dividends. More importantly, they have the resources and will to likely pay them in the future.

Click now for a Special Report packed with unconventional wisdom and insights you simply won’t get from your neighborhood financial planner.

See our Top 5 now – the report is FREE >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.